GlassScriptPhysician profile
Diana C Young
NPI 1013917202
$2,035.30
in general payments reported to CMS, 2019-2025
26 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $170 · 2021: $16.18 · 2022: $160 · 2023: $255 · 2024: $136 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $577.19 | 2019-2025 | Repatha |
| Novo Nordisk INC | $229.94 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $183.43 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $140.33 | 2022-2024 | Breztri |
| Janssen Pharmaceuticals, INC | $108.90 | 2023-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.62 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $100.96 | 2020-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $62.56 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $53.37 | 2022-2024 | Eliquis |
| Exact Sciences Corporation | $51.42 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $48.98 | 2023-2024 | Vraylar |
| Organon LLC | $47.91 | 2025 | Nexplanon |
| Xeris Pharmaceuticals, INC. | $44.12 | 2023-2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.02 | 2023-2025 | Xifaxan |
| Neurocrine Biosciences, INC. | $40.25 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $26.27 | 2024 | Trelegy Ellipta |
| Pfizer INC. | $22.99 | 2024 | |
| Inspire Medical Systems, INC. | $22.53 | 2025 | Inspire |
| Ascensia Diabetes Care US INC. | $18.11 | 2025 | |
| Amarin Pharma, INC. | $16.79 | 2020 | |
| Philips North America LLC | $16.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.53 | 2025 | |
| Dexcom, INC. | $15.47 | 2025 | Dexcom G6 Transmitter |
| Actelion Pharmaceuticals US, INC. | $15.29 | 2023 | Uptravi, Opsumit |
| Phathom Pharmaceuticals, INC. | $13.86 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $13.67 | 2025 | Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.